{"page":{"totalFilteredElements":335},"studies":[{"active":true,"description":"Prospektive NIS zu klinischen Outcomes bei Patienten mit fortgeschrittenem nicht kleinzelligem Lungenkrebs (NSCLC) mit EGFR Mutation unter Behandlung mit zugelassenem Amivantamab-haltigen Therapieschemata im Rahmen der standardmäßigen klinischen Praxis","eudractNumber":null,"id":11841,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T11:41:58+01:00","shortTitle":"Lepidoptera","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Krebsassoziierte Fatigue: Wissen, Einstellungen, Bedürfnisse und aktueller Stand der Fatigue-Versorgung in Deutschland
VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":7915,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-04-01T11:30:20+02:00","shortTitle":"LiFT- Projekt","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

Registerstudie zur Ätiologie, biologischem\nErkrankungsprofil und klinischem Verlauf bei „Low grade“-Gliomen: die\nLoG-Glio-Epidemiologie und Outcome-Studie (LoG-Glio)

","eudractNumber":null,"id":2611,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02686229","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2017-01-15T10:56:49+01:00","shortTitle":"LoG-Glio","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive. A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer.
","eudractNumber":"2024-519773-19","id":11702,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06901531","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-16T11:09:29+02:00","shortTitle":"Lucerna","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"

Histologische, immunphänotypische und molekulargenetische\nCharakterisierung kutaner\nLymphom

","eudractNumber":null,"id":2695,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-10-14T09:41:37+02:00","shortTitle":"Lymphomsequenzierung","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
","eudractNumber":null,"id":7962,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05578976","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-07-20T13:49:14+02:00","shortTitle":"M20-621","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
Non-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic Agents
","eudractNumber":"2021-005725-24","id":7304,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05283720","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2023-12-19T13:21:36+01:00","shortTitle":"M22-132","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma","eudractNumber":"2021-005587-22","id":7992,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05259839","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2022-11-09T13:52:09+01:00","shortTitle":"M22-947","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository to prospectively collect HCT data, complications and outcomes pertinent \nto graft-versus-host disease from allogeneic HCT patients for future \nanalysis
To prospectively collect and store blood for future analysis from allogeneic HCT patients","eudractNumber":null,"id":1727,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2015-01-27T13:54:30+01:00","shortTitle":"MAGIC adult","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Studie der Prävalenz der Mangelernährung bei gastroenterologischen Tumoren und die Auswirkungen einer ernährungstherapeutischen Therapie.","eudractNumber":null,"id":11415,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-07-23T08:59:24+02:00","shortTitle":"MALGAT","therapeutical":false,"therapyLines":[]}]}